The Filing Desk

Ardelyx vs Travere Therapeutics

Ardelyx ARDX · Travere Therapeutics TVTX · Pharmaceuticals

Travere Therapeutics reported revenue of $491 million in fiscal 2025, 1.2 times Ardelyx's $407 million in fiscal 2025. Ardelyx's revenue grew 22.1% in its latest year, and Travere Therapeutics' grew 110.5%. Ardelyx had an operating margin of -10.1%, against -12.8% at Travere Therapeutics.

Side by side

ArdelyxTravere Therapeutics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$407M$491M
Revenue growth22.1%110.5%
Revenue growth a year, last 5 years121.7%19.9%
Gross margin90.3%97.9%
Operating margin−10.1%−12.8%
Net margin−15.1%−5.2%
Free cash flow−$44M—
Free cash flow margin−10.8%—
Return on capital−36.1%—
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count2.5%13.1%
Last close$3.09$50.65
P/E at the last close——
Insider trades, last 12 months—sold $95.9 million
Piotroski F-score2 of 97 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
ArdelyxTravere Therapeutics
Operating margin
Percent of revenue
ArdelyxTravere Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
ArdelyxTravere Therapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Ardelyx and Travere Therapeutics pages.